Breaking News

Financial Report: Emergent BioSolutions

August 8, 2014

Cangene ops boost revenue in the quarter

Emergent BioSolutions

2Q Revenues: $110.3 million (+34%)

2Q Earnings: $5.0 million (+51%)

YTD Revenues: $164.2 million (+31%)

YTD Loss: $15.2 million (earnings were $2.4 million YTD13)

Comments: This was the first full quarter of combined operations with Cangene.Product sales were $78.3 million, up 19%. Revenue from BioThrax was $67.5 million in the quarter, up 3%. Contract manufacturing revenue was $9.2 million in the quarter. R&D expenses were $37.4 million, up 23% primarily due to higher contract service costs, and includes increased technology and development expenses in both the Biodefense and Biosciences divisions.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks